Boston Scientific Corporation (NYSE:BSX) stock is currently pricing at roughly $26.59. Our analysis shows that the stock is widely covered by equity research firms, and target prices are revealing. From a summary standpoint, we track the median one-year price target among 20 analysts covering the company at $29.50. That suggests shares of the stock may have another 10 percent to the upside left to run. Of those analysts we surveyed, the highest price target on recordsits at $31.00, which would imply another 83 percent in upside potential. If we look for a little more qualitative data on the range of expectations, we find in analyst notes that the stock has 10 “Buy” ratings in place. At the same time, 9 rate the stock a “strong buy”, suggesting more conviction in the story. As for the doubters, 5 equity research analyst firms call this stock a “Hold” and 0 consider it bad enough to warrant a “Sell” rating.

Analysts at Argus took a look at BSX shares in a research note released on Sep 01, 2016, and issued a Buy rating to this company. Guggenheim analysts provided their own take on company recently as well. In a research note published on Jun 09, 2016,the house assigned a Buy rating to this stock. According to a piece that hit the wires on Oct 05, 2015, researchers at Raymond James reconsidered their prior rating on the stock, and upped it from Outperform Perform to Strong Buy.

Boston Scientific Corporation (BSX) Cap Table Analysis

Breaking down the capitalization table is our next goal. From a bird’s eye view, Executives hold 0.83 percent of the stock.

If we take a more granular look, Pete M. Nicholas is one of the largest owners in company capital stock among insiders. According to U.S. Securities and Exchange Commission (SEC) filings, this investor owns 3,486,965 shares, representing a total current market value of roughly $92718399.35. Mr. Michael F. Mahoney is another major player among company insiders, currently holding 1,672,443 shares as of 0.12%, carrying a current market value of $44470259.37. Mr. J. Raymond Elliott is currently ranked as the number three insider in terms of representation on the cap table for the stock, holding 603,676 shares, valued at around $16051744.84 as of recent close.

We noted a few insider transactions for the stock recently as well.

In a transaction on 2017-05-01, the company’s EVP, GC & Chief Admin Officer Pratt Timothy A. sold 10,000 company shares for 263700. That means, once accounting for this transaction, the EVP, GC & Chief Admin Officer is left with a stake of 225,846 shares, carrying a current total market value of $6005245. In addition, by means of a transaction dated 2017-05-01, EVP & President, MedSurg Phalen Michael P. sold 15,500 shares worth $408740. After that transaction, this investor is left with a total holding of 104,340 shares, representing a total investment value of $2774400.6. We also noted a 2017-04-26 transaction in which BSX EVP & President, MedSurg Phalen Michael P. sold 34,773 shares at a stock price of $26, carrying a total value of $904100, after which, this insider’s investment stands at 104,340 shares, with an overall financial value of $2774401.

Boston Scientific Corporation (NYSE:BSX) Earnings View 

In the company’s last quarter, BSX EPS moved to $0.29 from $0.30 compared sequentially with the prior quarter. Revenues for the company came in at $2.16BM. This stacks up against $2.19BM, on a sequential basis.

How does this compare with bottom and top-line expectations? Well, according to what we could find, analysts had been looking for the company to post net income of about $0.30 per share on $2.08BM in revenue. That sets up an interesting next quarter report card. We would note that analysts seem to be projecting earnings, on average, for this quarter in the range of $0.30 to $0.32. On a year-over-year basis, that compares with an EPS comp of $0.27.